Merck KGaA and Aqilion AB partner in potential €960m deal
2023-02-16
临床1期引进/卖出
Preview
来源: PMLiVE
Merck KGaA and Aqilion AB have entered into an exclusive licence and strategic research partnership to advance small molecule inhibitors of the TAK1 protein, thought to play a central role in various inflammatory responses.
Under the terms of the agreement, Aqilion will receive an upfront payment of €10m from Merck KGaA and will be eligible to receive up to €950m in potential milestone payments, as well as tiered royalties on global net sales.
The partnership, which combines the Swedish biotech’s experience in the discovery of selective TAK1 inhibitors with Merck KGaA's drug discovery and development capabilities, will aim to develop therapeutics for a broad range of autoimmune and inflammatory diseases, including those that are neurological.
Aqilion will be responsible for the design and synthesis of the novel small molecule TAK1 inhibitors, while Merck KGaA will lead preclinical pharmacology and biology studies.
Commenting on the recent partnership, Aqilion’s chief executive officer, Sarah Fredriksson, said: “We are delighted and proud to announce this collaboration with Merck as it validates our business strategy of generating highly innovative discovery projects in combination with pro-active business development and early deal-making.
“We are looking forward to working with Merck as this will speed up the process of bringing novel effective treatments to conditions with high unmet medical needs.”
Aqilion’s pipeline currently consists of four programmes in various phases of development, all of which are focused on innovative treatments for chronic inflammatory diseases for which few or no treatments are available.
This includes AQ280, a JAK1 small molecule inhibitorJAK1 small molecule inhibitor initially being assessed as a potential treatment for eosinophilic oesophagitis, an inflammatory disease of the oesophagus.
A phase 1 dose escalation study to determine the tolerability and safety of the candidate began in August last year, the company said, with results expected towards the middle of 2023.
“Our first phase 1 clinical trial has begun, which means that Aqilion is now a biopharmaceutical company that engages in clinical development,” Fredriksson said at the time. “I am both proud and pleased that we have also succeeded in establishing a pipeline with an innovative profile and a clear focus within chronic inflammatory diseases, including programmes from discovery to early clinical development.”
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。